|
Middle Cerebral Artery Occlusion
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of Sesn2 reduced Nrf2, Srx1 and Trx1 levels in rat cerebral cortex in MCAO model.
|
29917204 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.020 |
Biomarker
|
disease |
BEFREE |
For in vivo studies, siRNA for Srxn1 or negative control siRNA was injected intracerebroventricularly 24h before middle cerebral artery occlusion (MCAO).
|
28552673 |
2017 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, whether Srxn1 is involved in regulating hyperglycemia-induced podocyte injury and participates in diabetic nephropathy remains unknown.
|
31284950 |
2019 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, whether Srxn1 is involved in regulating hyperglycemia-induced podocyte injury and participates in diabetic nephropathy remains unknown.
|
31284950 |
2019 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these results provide a rationale for the exploration of SRXN1 as a novel molecular target that can be used to enhance the effectiveness of cardiac stem/progenitor cell therapy for ischemic heart disease.
|
29772252 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The abnormal elevation of sulfiredoxin (Srx/SRXN1)-an antioxidant enzyme whose main function is to protect against oxidative stress-has been shown to be closely correlated with the progression of several types of cancer, including human cervical cancer.
|
28448437 |
2017 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Data shows silencing Srxn1 resulted in a significant increase in cerebral infarction, neurological deficits, histological injury, and oxidative stress injury 24h after ischemic stroke.
|
28552673 |
2017 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Six-day-old Wistar rats were pre-treated with caffeine and exposed to 80% oxygen for 24 and 48 h. Caffeine reduced oxidative stress marker (heme oxygenase-1, lipid peroxidation, hydrogen peroxide, and glutamate-cysteine ligase catalytic subunit (GCLC)), promoted anti-oxidative response (superoxide dismutase, peroxiredoxin 1, and sulfiredoxin 1), down-regulated pro-inflammatory cytokines, modulated redox-sensitive transcription factor expression (Nrf2/Keap1, and NFκB), reduced pro-apoptotic effectors (poly (ADP-ribose) polymerase-1 (PARP-1), apoptosis inducing factor (AIF), and caspase-3), and diminished extracellular matrix degeneration (matrix metalloproteinases (MMP) 2, and inhibitor of metalloproteinase (TIMP) 1/2).
|
28106777 |
2017 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
Data shows silencing Srxn1 resulted in a significant increase in cerebral infarction, neurological deficits, histological injury, and oxidative stress injury 24h after ischemic stroke.
|
28552673 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The abnormal elevation of sulfiredoxin (Srx/SRXN1)-an antioxidant enzyme whose main function is to protect against oxidative stress-has been shown to be closely correlated with the progression of several types of cancer, including human cervical cancer.
|
28448437 |
2017 |
|
Cerebrovascular Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
NRF2 and SRXN1 polymorphisms, previously thought to be associated with human disease, appear to be associated particularly with cerebrovascular disease.
|
27226772 |
2016 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The association of genotypes of NRF2 and SRXN1 with cardiovascular conditions was studied in a Finnish cohort of 336 subjects with diagnosed hypertension and 480 normotensive controls from the Tampere adult population cardiovascular risk study (TAMRISK).
|
27226772 |
2016 |
|
Drug-Induced Liver Disease
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Strong activation of GFP-Srxn1 expression by DILI compounds typically correlated with suppression of NF-κB nuclear translocation, yet reversely, activation of NF-κB by TNFα did not affect the Nrf2 response.
|
26026609 |
2016 |
|
Infection by Cryptococcus neoformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study we have identified and functionally characterized the role of sulphiredoxin, Srx1, in oxidative stress resistance of Cryptococcus neoformans causing fungal meningoencephalitis and regulation of peroxiredoxins, Tsa1 and Tsa3, and thioredoxins, Trx1 and Trx2.
|
23998805 |
2013 |
|
Malignant neoplasm of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The NRF2 rs6721961 genotype TT was associated with increased risk of breast cancer [P = 0.008; OR, 4.656; confidence interval (CI), 1.350-16.063] and the T allele was associated with a low extent of NRF2 protein expression (P = 0.0003; OR, 2.420; CI, 1.491-3.926) and negative SRXN1 expression (P = 0.047; OR, 1.867; CI = 1.002-3.478).
|
22964583 |
2012 |
|
Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The NRF2 rs6721961 genotype TT was associated with increased risk of breast cancer [P = 0.008; OR, 4.656; confidence interval (CI), 1.350-16.063] and the T allele was associated with a low extent of NRF2 protein expression (P = 0.0003; OR, 2.420; CI, 1.491-3.926) and negative SRXN1 expression (P = 0.047; OR, 1.867; CI = 1.002-3.478).
|
22964583 |
2012 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, tumor-infiltrating T cells isolated from a RCC patient were also able to kill SRXN1 expressing tumor cells.
|
21595034 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia.
|
21742584 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, tumor-infiltrating T cells isolated from a RCC patient were also able to kill SRXN1 expressing tumor cells.
|
21595034 |
2011 |